靶向治疗对复发性耐药性卵巢癌的治疗价值

发布时间：2018-05-20 21:37

本文选题：靶向治疗 + 卵巢肿瘤　；参考：《中国实用妇科与产科杂志》2015年03期

【摘要】：卵巢癌复发率高,预后差,多数患者在反复间断化疗后最终都会出现耐药。近年来靶向药物在复发性耐药性卵巢癌的临床试验中取得了较为可喜的结果。广泛研究的靶向药物有血管内皮生长因子受体抑制剂如贝伐单抗,DNA损伤修复抑制剂如奥拉帕尼、Veliparib,血管生成素抑制剂如Trebananib,叶酸受体抑制剂如Vintafolide等等。近期研究显示,这些药物可延长铂耐药卵巢癌患者的无疾病间期。其中贝伐单抗联合单药化疗是目前临床应用较为成熟的治疗方案。文章重点介绍靶向治疗在复发性耐药性卵巢癌临床研究中的最新进展。
[Abstract]:The recurrence rate of ovarian cancer is high and the prognosis is poor. Most patients will eventually develop drug resistance after repeated intermittent chemotherapy. In recent years, targeted drugs have achieved gratifying results in clinical trials of relapsed ovarian cancer. Widely studied targeted drugs include vascular endothelial growth factor receptor inhibitors such as bevacizumab DNA damage repair inhibitors such as olapanil Veliparibb angiopoietin inhibitors such as Trebananib folic acid receptor inhibitors such as Vintafolide and so on. Recent studies have shown that these drugs prolong the disease-free interval in patients with platinum-resistant ovarian cancer. Among them, bevacizumab combined with single drug chemotherapy is a mature clinical treatment. This article focuses on the latest progress of targeted therapy in the clinical study of recurrent ovarian cancer with drug resistance.
【作者单位】：中国医学科学院肿瘤医院;
【分类号】：R737.31

【共引文献】